Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baupost Group Buys Over 16 Mln Shares of Idenix Pharmaceuticals Inc (IDIX)

Baupost Group, a fund managed by Seth Klarman, is a large shareholder of Idenix Pharmaceuticals Inc (NASDAQ:IDIX). The fund disclosed, in a new filing with the Securities and Exchange Commission, revealed that it holds 53.33 million shares of Idenix Pharmaceuticals Inc (NASDAQ:IDIX), equivalent to 35.38% of the common stock.

At the end of January, Idenix Pharmaceuticals Inc (NASDAQ:IDIX)  entered into a subscription agreement with certain entities managed by The Baupost Group, L.L.C. The agreement related to the issuance and sale of an aggregate of 16.42 million shares of the company’s common stock at $6.50 per share. Thereafter, Baupost Group is entitled to 35% of the company’s common stock upon completion of the offering closed on January 31. Earlier, the fund had raised its stake to 36.91 million shares from 26.8 million.

BAUPOST GROUP

The company received $106.7 million of net proceeds from the offering and will use the offering for  general corporate purposes, including clinical trial costs and ongoing and future patent litigation expenses.

Baupost has also been granted observer rights, with respect to meetings of the board of directors of the company and the committees of the company’s board of directors. Baupost Group, acquired the common stock to invest in the ordinary course of business.

Of all the hedge funds we track, Bain Capital’s Brookside Capital is another hedge fund which stands on the second spot, amassing 12.66 million shares of Idenix Pharmaceuticals Inc (NASDAQ:IDIX), at the end of the third quarter of 2013. 12 West Capital Management, led by Joel Ramin, initiated a stake in the company in the third quarter, and holds 1.78 million shares.

Baupost Group is the 11th largest hedge fund in the world.

Last month, Seth Klarman trimmed his stake in Enzon Pharmaceuticals Inc (NASDAQ:ENZN) to 4.34 million shares from over 7.69 million shares. On the same day the fund revealed in a separate filing that it initiated a stake in Kindred Biosciences Inc (NASDAQ:KIN) and owns 2.9 million shares of the company.

Disclosure: none

Recommended Reading:

Ra Capital Management Initiates Stake in Furiex Pharmaceuticals Inc (FURX) After the Stock Jumped

Deerfield Management Discloses Stake in Post-IPO Auspex Pharmaceuticals Inc (ASPX)

Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...